Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryPharmaceuticals
SectorMedical
Phone+1-720-4376500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees22
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions
What is Ampio Pharmaceuticals' stock symbol?
Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."
How were Ampio Pharmaceuticals' earnings last quarter?
Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) issued its quarterly earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter. View Ampio Pharmaceuticals' Earnings History.
When is Ampio Pharmaceuticals' next earnings date?
Has Ampio Pharmaceuticals been receiving favorable news coverage?
News coverage about AMPE stock has trended very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ampio Pharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Ampio Pharmaceuticals.
Who are some of Ampio Pharmaceuticals' key competitors?
Some companies that are related to Ampio Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).
What other stocks do shareholders of Ampio Pharmaceuticals own?
Who are Ampio Pharmaceuticals' key executives?
Ampio Pharmaceuticals' management team includes the folowing people:
- Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 67)
- Mr. Thomas E. Chilcott III, CFO, Treasurer & Sec. (Age 51)
- Ms. Holli Cherevka, Chief Operating Officer (Age 36)
Who are Ampio Pharmaceuticals' major shareholders?
Which institutional investors are selling Ampio Pharmaceuticals stock?
How do I buy shares of Ampio Pharmaceuticals?
Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ampio Pharmaceuticals' stock price today?
One share of AMPE stock can currently be purchased for approximately $0.34.
How big of a company is Ampio Pharmaceuticals?
What is Ampio Pharmaceuticals' official website?
How can I contact Ampio Pharmaceuticals?
Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500.
MarketBeat Community Rating for Ampio Pharmaceuticals (NYSEAMERICAN AMPE)
MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days.
